Takeda received U.S. Food and Drug Administration (FDA) approval for Gammagard Liquid ERC [immune globulin infusion (human)]. The therapy has less than or equal to 2 µg/mL IgA in a 10% solution and is the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content. Gammagard Liquid ERC is designed as replacement therapy for people two years of age and older with primary immunodeficiency (PI).  As a ready-to-use liquid, Gammagard Liquid ERC may help ease the ad...